Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect,

December 18, 2007 - Gaithersburg, Maryland - Panacea Pharmaceuticals' lung cancer diagnostic test, LC Detectsm, has been named one of Time Magazine's Ten Biggest Medical Breakthroughs of 2007. LC Detect^sm is a simple blood test to facilitate the identification of lung cancer, even among individuals with early-stage disease... LC Detect^sm measures levels of human aspartyl (asparaginyl) &#beta;-hydroxylase (HAAH), a cancer molecular marker, in blood. HAAH has been detected by immunohistochemical staining in a broad range of cancers, including lung cancer, and has been shown to be highly specific and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals... Panacea's Press Release -

Infinity and Medimmune, Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor’s Potential Anti-Tumor Activity in Patients with Advanced NSCLC

December 19, 2007 – Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and MedImmune, Inc. announced that the companies have initiated the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) ...The goal of this open-label, multi-center clinical trial is to evaluate the anti-tumor activity of IPI-504 in patients with NSCLC... Infinity 's Press Release - MedImmune's Press Release -

Theravance, GSK1160724, Phase 1 Clinical Study With Investigational Medicine For Respiratory Disease

December 12, 2007 - Theravance, Inc. (NASDAQ: THRX) announced that GlaxoSmithKline plc (GSK) initiated subject screening in a Phase 1 clinical study designed to assess the safety, tolerability, and pharmacokinetics of an investigational, inhaled bronchodilator, GSK1160724, for the treatment of chronic obstructive pulmonary disease (COPD)...GSK1160724 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory diseases such as COPD and asthma... Theravance's Press Release -

Discovery Labs, Aerosurf Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome

December 3, 2007 — ...Aerosurf is an aerosolized formulation of Discovery Lab’s novel KL4 surfactant technology that is delivered non-invasively via novel aerosol generating technology and employs nasal continuous positive airway pressure (nCPAP). Aerosurf, like Discovery’s lead product Surfaxin®, is a precisionengineered synthetic, peptide-containing surfactant which is designed to closely mimic the essential attributes of human lung surfactant.... Discovery Labs' PDF -

Rigel , Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer

Dec. 6 , 2007 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its corporate partner, Pfizer (NYSE: PFE), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for the treatment of allergic asthma. R343 is the third product candidate in Rigel's clinical portfolio... Rigel's Press Release -

IDM Pharma, IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients

Nov. 2 - IDM Pharma, Inc. (Nasdaq: IDMI) announced updated results from the Phase 2 study of its investigational agent IDM-2101 which showed the vaccine was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients... IDM Pharma's Press Release -